Detecting Counterfeit Pharmaceuticals in Sub-Saharan Africa
May 20, 2020
Technology, Policy, and a Need for Vigilance in Detecting Counterfeit Antimalarials in Sub-Saharan Africa
|PDF file||0.6 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
Malaria remains a significant global health problem, despite continued efforts made for its eradication. Nearly half of the world's population lives in malaria-endemic regions, with the burden resting primarily in low- and middle-income countries in sub-Saharan Africa. Malaria and the costs of treatment trap families in a cycle of illness, suffering, and poverty. Despite the efficacy of malaria treatments, malaria remains highly virulent due to the prevalence of substandard and falsified medicines. For decades, drug counterfeiting has remained underestimated and ignored, though fraudulent pharmaceuticals are on the rise in many countries because, simply put, it is a profitable business and there is high demand, particularly for lifesaving drugs such as antimalarials. These medicines, which may be produced or distributed deliberately or unintentionally, neither prevent nor cure malaria in the individuals who take them and often cause significant adverse effects and premature death. They can also cause the parasite to develop drug resistance, which is especially dangerous for those living in malaria-endemic countries.
However, there are ways in which countries can stem the importation, production, and dissemination of fraudulent antimalarials. In this report, we will first outline the problem at hand before diving into a case study of Nigeria, an impressive example of how to reduce the prevalence of substandard and falsified pharmaceuticals in a given country. We will then finish the report by discussing, at a high level, what remains to be done to continue making strides toward malaria eradication.
The research described in this report was conducted by the Pardee Initiative for Global Human Progress within the Pardee RAND Graduate School.
This report is part of the RAND Corporation Working paper series. RAND working papers are intended to share researchers' latest findings and to solicit informal peer review. They have been approved for circulation by RAND but may not have been formally edited or peer reviewed.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.